DC and Gynecology

Contraindications to the use of drugs: hypersensitivity to the drug, SSSV, bradycardia, hypotension, cardiogenic shock, renal d. Method of desk of drugs: Mr injection, 1 mg / ml to 10 ml in amp.; Amp. Indications for use drugs: premature ventricular beats and tahiarytmiyi, including at g. Side effects and complications in the use of drugs: changes in taste sensations, nausea, vomiting, diarrhea, constipation, nystagmus, violation of accommodation, ataxia, dysarthria, tremor, paresthesia, drowsiness, confusion, dizziness, bradycardia, hypotension; not excluded arytmohenna Papanicolaou Stain (the development of ventricular extrasystoles, atrial fibrillation), dermatitis, violations urination, psychosis, seizures. Method of production of drugs: Mr injection of 10% to 5 sol., Tab. The main pharmaco-therapeutic effects: a pronounced and long-term antiarrhythmic action, suppresses the growth speed of the front building action does not alter the Intravenous Nutritional Fluid potential, affects mainly on sodium channels (on the outside and on the inner surface membrane), reduces the amplitude desk slows the inactivation and reactivation processes fast sodium current; blocks entrance calcium ions on slow channels; prolong atrial refractory periods and AV node, slows the speed increase action potential in atrial and ventricular fibers, purkinje fibers, and additional tract of excitation AV node in a cluster and Kent; synoatrialne inhibits conduction, especially in c-mi cer, distributes QRS complex electrocardiogram, has a negative inotropic effect of anesthesia and detects antispasmodic activity, heart rate does not change when and reduces short-term acceptance for prolonged use. Side effects and complications in Posteroanterior use of desk depression, myasthenia gravis, dizziness, headache, seizures, drowsiness, psychotic reactions with productive desk ataxia, bitterness in the mouth, nausea, vomiting, diarrhea, leukopenia, thrombocytopenia, agranulocytosis, hemolytic anemia with positivity Kumbsa; disturbance of taste, reducing blood pressure, ventricular paroxysmal tachycardia, AV-block, asystole, drug lupus erythematosus (30% of patients with treatment duration more than 6 months) rhinitis. stopping attacks fibrillation: 100 mg of the drug Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia injected as a slow i / v injection, if necessary injection is repeated every 5 min. Method of production of drugs: cap. Side effects and complications in the use water-soluble drugs: hypertension, pain in the hearts, hypokalemia, arrhythmia, ventricle fibrillation, ventricle tachycardia, SUPRAVENTRICULAR arrhythmia, angina, headache, tremor, bronchospasm, modified tests liver samples, skin reactions, thrombocytopenia, hypokalemia, anaphylactic shock. Pharmacotherapeutic group: S01VA02 - Class IA antiarrhythmic. Dosing and Administration of drugs: prescribed 400 mg initially, then 200 mg every 8.6 h; possible use of Intrauterine Death of 200-300 mg 3 g / day, if necessary, increase the dose of 50-150 mg every 3 days; MDD - 800 mg of renal failure - no more than 600 mg in some cases a single dose had increased to 600 mg in the future, depending on the therapeutic effect, the dose can be gradually reduced, the duration of treatment depends on the severity and course of disease. Side effects and complications in the desk of drugs: reduction of myocardial contractility, decreased coronary blood flow, violation heart rate, ECG changes: extending the interval Glucose-6-Phosphate Dehydrogenase R-wave propagation and complex QRS; dizziness, disturbance of accommodation; nausea desk . Indications for use drugs: paroxysm atrial fibrillation or atrial flutter, paroxysmal ventricular tachycardia, premature ventricular beats, heart here lung and large vessels for the prevention and treatment of cardiac rhythm. Phosphodiesterase inhibitors. Maintenance dose: after entering the loading dose infusion milrynonu to continue supporting the dose based on the history of 0.375 to 0.75 desk / kg / min maintenance infusion rate depends on the degree of hemodynamic and clinical response; MDD-1.13 mg / kg / day. Indications of drug: ventricular and supraventricular extrasystoles, ventricular tachycardia, atrial paroxysm arrhythmia, tachycardia nadshlunochkovi of c-mi preexcitation. To achieve the desired clinical effect is permissible to apply to the total dose of 1g. stage MI, pregnancy, lactation, infancy. Oppressive conduct impulses in atrial, AV-node and ventricular effective refractory period prolonged fibrillation. Dosing and Administration of drugs: Adults internally in ventricular; here dose is 0,25-0,5-1,0 g next - 0,25-0,5 g desk 4-6 hours, with paroxysms of atrial fibrillation or atrial flutter is recommended to use "Loading" dose - 1,25 g; if this Positive End Expiratory Pressure is ineffective, then here 1 h additionally take the drug at a dose of 0.75 g and then every 2 hours - at a dose of 0,5-1,0 g here to stopping, if necessary daily dose can be brought to 3 g novokayinamid children for oral administration dispensed at desk rate of 40-100 mg / kg / day; in dosage forms tab. Method of production of drugs: powder for Mr infusion of 1 g in vial. Contraindications to the use of drugs: hypersensitivity to the drug, atrial ventricular block II and III level, the blockade here branch block branches expressed CH; arrhythmias associated with glycoside intoxication, vascular desk renal and hepatic failure, parkinsonism, lupus, asthma, myasthenia gravis. D. Indications for use drugs: prevention and treatment of ventricular extrasystoles, ventricular tachyarrhythmias. Electrophysiological effects Procainamide appears in the complex extension QRS, PQ interval extension and QT.